Literature DB >> 18475705

Inhibition of the production of mediators of inflammation by corticosteroids is a glucocorticoid receptor-mediated process.

G S Madretsma1, A P Dijk, C J Tak, J H Wilson, F J Zijlstra.   

Abstract

In order to find an explanation for corticosteroid resistance we assessed whether inhibition by dexamethasone (DEX) of the stimulated production of TNF- proportional, variant, IL-6, PGE(2) and LTB(4) by peripheral blood mononuclear cells (MNC) depends on binding to the glucocorticoid receptor (GR), and whether it is determined by the number or the affinity of the GR of these cells. GR number and affinity of MNC were determined by means of a whole cell DEX binding assay. MNC were incubated with DEX and LPS or A23187 in the absence or presence of RU486, a potent steroid antagonist. DEX caused a concentration dependent inhibition of TNF- proportional, variant, IL-6 and PGE(2) production but had no effect on LTB(4) production. RU486 significantly blocked the effect of DEX, but no correlations were found between the inhibition of mediator release and the K(d) or receptor number.

Entities:  

Year:  1996        PMID: 18475705      PMCID: PMC2365783          DOI: 10.1155/S0962935196000166

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  14 in total

1.  cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.

Authors:  M K O'Banion; V D Winn; D A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  Glucocorticoid effects on the production and actions of immune cytokines.

Authors:  P M Guyre; M T Girard; P M Morganelli; P D Manganiello
Journal:  J Steroid Biochem       Date:  1988       Impact factor: 4.292

Review 3.  Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease.

Authors:  J E Lennard-Jones
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

Review 4.  The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology.

Authors:  R A Lewis; K F Austen
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

5.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

6.  Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma.

Authors:  K F Kerrebijn; E E van Essen-Zandvliet; H J Neijens
Journal:  J Allergy Clin Immunol       Date:  1987-04       Impact factor: 10.793

Review 7.  Corticosteroid therapy in asthma.

Authors:  N E Dunlap; J D Fulmer
Journal:  Clin Chest Med       Date:  1984-12       Impact factor: 2.878

8.  Cortisol receptor resistance: the variability of its clinical presentation and response to treatment.

Authors:  S W Lamberts; J W Koper; P Biemond; F H den Holder; F H de Jong
Journal:  J Clin Endocrinol Metab       Date:  1992-02       Impact factor: 5.958

9.  Corticosteroid prescribing in rheumatoid arthritis--the fiction and the fact.

Authors:  M A Byron; A G Mowat
Journal:  Br J Rheumatol       Date:  1985-05

Review 10.  Role of eicosanoids in human and experimental colitis.

Authors:  R Schumert; J Towner; R D Zipser
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

View more
  1 in total

Review 1.  Allosteric pathways in nuclear receptors - Potential targets for drug design.

Authors:  Elias J Fernandez
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.